



**BIO-PATH HOLDINGS TO ANNOUNCE FIRST QUARTER 2016 FINANCIAL RESULTS ON
MAY 11, 2016**

HOUSTON—May 4, 2016 – Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, May 11, 2016 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2016, and to provide a business overview.

To access the live conference call, please call (844) 260-6671 (domestic) or (508) 915-0912 (international) at least five minutes prior to the start time, and refer to conference ID 5580108. A live audio webcast of the call will also be available on the Investors' section of the Company's website, www.biopathholdings.com. An archived webcast will be available on the BioPath website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path's lead product candidate, BP1001 (Liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. Bio-Path's second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.

For more information, please visit the Company's website at <http://www.biopathholdings.com>.

###

Contact Information:

Investors

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

Will O'Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Media

Tony Plohoros
6 Degrees
908-591-2839
tplohoros@6degreespr.com